A comprehensive review published by the European Society of Human Reproduction and Embryology (ESHRE) finds limited high-quality evidence supporting most routine in vitro fertilization (IVF) add-ons, prompting renewed calls from medical experts for rigorous clinical trials and transparent patient counseling before these supplementary procedures are offered in standard practice.
According to the ESHRE recommendations, patients undergoing fertility treatments are frequently offered various auxiliary laboratory techniques and clinical procedures—such as pre-implantation genetic testing for aneuploidy (PGT-A), endometrial scratching, and time-lapse embryo imaging—despite a persistent lack of robust randomized controlled trial data proving they improve live-birth rates. These optional extras can add substantial out-of-pocket costs to an already expensive medical process while offering unproven clinical benefits.
The Evidence Gap Surrounding IVF Add-Ons
Fertility clinics often market add-on therapies as cutting-edge advancements designed to boost success rates for patients struggling with infertility. However, according to the ESHRE guideline updates, many of these interventions enter widespread clinical use before large-scale, high-quality trials confirm their efficacy. For instance, while pre-implantation genetic testing is valuable for specific genetic conditions, its routine use as a blanket add-on for all IVF patients lacks definitive proof that it universally improves cumulative live-birth rates per egg retrieval.
Researchers emphasize that the absence of evidence does not automatically mean a treatment is ineffective, but it does mean patients cannot make fully informed financial or medical decisions without clear disclosures. Clinics face mounting pressure from professional societies to distinguish between experimental innovations and validated treatments.
Implications for Patient Counseling and Costs
Financial toxicity remains a major concern in reproductive medicine. According to patient advocacy groups and medical literature, optional laboratory procedures can increase the total cost of an IVF cycle by thousands of dollars. When clinicians recommend these services without adequate disclosure of their speculative nature, patients bear both the financial burden and the emotional toll of failed expectations.
To address this, the updated guidance urges reproductive endocrinologists and clinic directors to adopt standardized informed consent protocols. Physicians are encouraged to clearly outline what clinical endpoints a specific add-on targets, what the scientific literature actually shows, and whether the intervention carries any potential risks to embryo viability or patient health.
Future Outlook for Reproductive Medicine
The pushback against unverified IVF add-ons signals a broader shift toward evidence-based standardization in reproductive endocrinology. Professional organizations are actively developing frameworks to help clinics evaluate new laboratory technologies objectively before introducing them to the commercial market. As fertility specialists await the results of ongoing multicenter trials, the immediate priority across the field centers on transparent communication and protecting patients from paying for unproven medical interventions.